Here you’ll find answers to frequently asked questions about the BRAIN Biotech AG. If you have further questions, do not hesitate to contact us.
BRAIN Biotech AG is the parent company of the BRAIN Biotech Group. The group´s headquarter is located in Zwingenberg, South Hesse, Germany.
The companies and sites belonging to the division "BioProducts" are subsidiaries or operating sites of the specialty enzymes company Biocatalysts Ltd. in Cardiff, Wales (UK).
BRAIN Biotech AG has been founded in 1993 in Darmstadt, Germany.
BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange since February 9th, 2016. (BNN; ISIN DE0005203947 / WKN 520394)
Under the German Stock Corporation Act (Aktiengesetz), shares in a company are either in registered or in bearer form. Both forms of shares are prevalent in Germany and well established. Registered shares facilitate a better communication between the company and its stockholders and lead to improved transparency in regards to the company’s ownership structure.
We provide biological solutions and products based on microorgnisms and enzymes that enable industry to make their processes and products more sustainable.
We are the sought-after specialist in industrial biotechnology. With our service and product businesses, we successfully occupy niches with products that offer our customers high added value. We are more flexible than our competitors. We produce our innovative enzymes and proteins ourselves or together with our partners.
BRAIN Biotech AG focusses on the business-to-business (B2B) segment in industrial biotechnology. The corporate group develops and produces enzymes, proteins and microbial production strains for industrial applications with a focus on the food and beverage, health and life sciences and environmental sectors.
The Group divides its business activities into three operating segments plus a holding company. The level of innovation and scalability is reflected in these three segments.
The BioProducts segment comprises the product business with specialized enzymes and other proteins.
The BioScience segment comprises research-intensive, custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. We are the partner of choice when industry is looking for innovative biobased solutions.
The BioIncubator is our R&D pipeline of proprietary and partnered projects with high value creation potential. The research-intensive projects are driven forward at the Zwingenberg and Potsdam research sites.
Industrial biotechnology contributes to more sustainable industrial processes and products. BRAIN Biotech AG provides biological solutions and products based on microorganisms and enzymes that enable industry to make their processes and products more sustainable.
BRAIN Biotech is a market leader and trendsetter in the bioeconomy (bio-based economy). The concept of bioeconomy involves the use of biotechnology in the production of bio-based products. Our products and solutions directly address these United Nations´ SDGs: 2, 3, 6, 9 and 12.
Enzymes are proteins, which are often industrially produced from microbes.
Enzymes catalyze specific biochemical reactions. This is why they are also called biocatalysts. Microorganisms (microbes) are living organisms, existing in single-celled form or in cell-colony form; for example, bacteria or fungi. They are industrially produced via fermentation in so-called bioreactors.
Bioactive natural compounds ("bioactives") are present in small quantities e.g. in foods like fruits, vegetables, and whole grains, and can provide health benefits beyond the basic nutritional value.
Our Bioarchive contains approximately 53,000 comprehensively characterized microorganisms, chassis microorganism strains for the development of production organisms and genetic libraries with new enzymes and metabolic pathways.
The collection is being expanded in ongoing projects and allows the identification of previously uncharacterized enzymes and new access to previously uncultivable microorganisms.
Organic growth remains the primary driver of our strategy. We will continue to invest in our own product development and technological innovations, improving the speed, number of projects and innovations brought to market. In addition and for the time being, we currently focus on bolt-on acquisitions to add to our product offerings and improve economies of scale. By doing so, we will strive to best support our customers’ needs and to create value for our stakeholders.
Please have a look at the website section Management.
Please visit our website section Sustainability.
BRAIN Biotech AG’s fiscal year deviates from the calendar year. Our fiscal year starts on October 1st and ends on September 30th of the following year.
Please find BRAIN Biotech´s financial publications in the corresponding website section Financial Calendar & Publications
BRAIN Biotech Group deploys IFRS, International Financial Reporting Standards for its financial market communication.
Still have questions? Please do not hesitate to contact us.
You can also find explanations of technical terms in our glossary.
